Adeodata Rukyalekere Kekitiinwa
ID: UNCST-2019-R000799
|
Novel and Optimized Diagnostics in Pediatric Tuberculosis in Kampala, Uganda(NOD)
REFNo: HS1341ES
The study has the following objectives:
Objective 1: Evaluate and develop novel assays that diagnose TB by detecting Mycobacterium tuberculosis (MTB) bacterial products in non-sputum body fluids. Objective 2: Evaluate and develop novel assays that diagnose TB by detecting host biomarkers in non-sputum body fluids.
Objective 3: Identify combinations of assays that applied together could be used to diagnose TB among children with unconfirmed.
|
Uganda |
2021-05-18 |
2024-05-18 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Edith Wakida K
ID: UNCST-2019-R001225
|
Impact and process Evaluation of the Health-Professional Education Partnership Initiative – Transforming Ugandan Institutions Training Against HIV/AIDS
REFNo: HS1351ES
1. To evaluate the acceptability, appropriateness, feasibility, and implementation process of the HIV curriculum
2. To evaluate the acceptability, appropriateness, feasibility, and implementation process of building capacity of primary health care (PHC) providers to provide comprehensive HIV services and strengthen bidirectional linkages between health facilities and communities
3. To evaluate the acceptability, appropriateness, feasibility, and implementation process of the micro-research program
|
Uganda |
2021-05-18 |
2024-05-18 |
Medical and Health Sciences |
Non-Clinical Trial |
Non-degree Award |
|
Pontiano Kaleebu
ID: UNCST-2021-R013577
|
A phase I study to determine the safety and immunogenicity of the candidate Rift Valley Fever Virus (RVFV) vaccine ChAdOx1 RVF among healthy adult volunteers in Uganda.
REFNo: HS793ES
The primary objective of this study is to assess the safety profile of the candidate vaccine ChAdOx1 RVF in healthy adult volunteers in Uganda. This will be assessed through comparing the frequency of solicited, unsolicited and serious adverse events and changes from the baseline of laboratory safety measures between participants who will receive the active vaccine and those who will receive the placebo.
The Secondary objective is to assess the immunogenicity of the candidate vaccine ChAdOx1 RVF in healthy adult volunteers in Uganda. This will be assessed through quantification of antibodies to the GnGc proteins using ELISA, RVFV neutralising antibody titres and Ex vivo ELISpot and flow cytometry responses to GnGc.
|
Uganda |
2021-05-17 |
2024-05-17 |
Medical and Health Sciences |
|
Non-degree Award |
|
Allen Kabagenyi
ID:
|
Impoverishing and Catastrophic health expenditure on cancer care among persons affected by cancer in Uganda
REFNo: SS851ES
1. To determine the out of pocket expenditure associated with cancer care for persons affected by cancer, by type and stage;
2. To determine the proportion of cancer patients and or their families that experience catastrophic or impoverishing expenditure due to cancer related expenses by cancer type and stage;
3.To characterize the socio-economic interruptions experienced by persons affected by cancer in Uganda.
4.To examine the sociodemographic characteristics associated with cancer care burden in Uganda
5.To assess patients and care givers perceptions and attitudes of cancer care expenditures and health care in Uganda
|
Uganda |
2021-05-17 |
2024-05-17 |
Social Science and Humanities |
Non-Clinical Trial |
Non-degree Award |
|
Julia Dickson-Gomez
ID: UNCST-2019-R000775
|
Integration of buprenorphine into a multi-component harm reduction program for people who inject drugs in
Kampala, Uganda
REFNo: HS1229ES
To develop a combination HIV prevention intervention for PWID in Kampala Uganda, using the Consolidated Framework for Intervention Research. The combination intervention includes social network HIV/HCV testing, linkage to care for PWID and PrEP for HIV negative PWID. All participants will be offered safe injection equipment, condoms and HIV risk reduction education, and naloxone, buprenorphine, and CBT4CBT for heroin users.
2. To refine the intervention iteratively through implementation cycles using the CFIR framework to identify barriers and find solutions to implementation and scale-up.
3. To assess feasibility, acceptability and initial promise of the intervention with a 6-month pilot test.
|
USA |
2021-05-10 |
2024-05-10 |
Medical and Health Sciences |
|
Non-degree Award |
|
| View |
|
Sort By: |
|
|
|
| |
|